Cancer care has undergone a revolution, driven by advances in the understanding of cancer biology and new therapeutics derived from that understanding. Many patients diagnosed as having cancer in the 1990s received relatively ineffective, toxic chemotherapeutics. Today, a patient encountering an oncologist might undergo a tumor biopsy with the goal of evaluating hundreds of oncogenic mutations. That patient then receives one of the many targeted therapeutics (eg, kinase inhibitors, monoclonal antibodies) or immuno-oncology agents in the ever-expanding therapeutic armamentarium, many developed within the past decade.
Sledge GW. Patients and Physicians in the Era of Modern Cancer Care. JAMA. 2019;321(9):829–830. doi:10.1001/jama.2018.17334
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.